发明名称 PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY.
摘要 <p>The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclohexyl-Λ/3-[2-(3-fluorophenyl)ethyl]-Λ/-(2-{ [2-(4- hydroxy-2-oxo-2,3-dihydro- 1,3-benzothiazol-7-yl)ethyl]amino} ethyl)-β-alaninamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCRl antagonist; a chemokine antagonist (not CCRl); a corticosteroid; a CRTh2 antagonist; a DPI antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist; a p38 inhibitor; a PDE inhibitor; a PPARγ agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease (for example chronic obstructive pulmonary disease (COPD) or asthma); to certain salts of A/-Cyclohexyl-N3-[2-(3-fluorophenyl)ethyl]- N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-l,3-benzothiazol-7-yl)eth yl]amino}ethyl)-β- alaninamide and to an intermediate useful in the manufacture of this pharmaceutically active substance and salts thereof.</p>
申请公布号 MX2010013416(A) 申请公布日期 2010.12.21
申请号 MX20100013416 申请日期 2009.06.18
申请人 ASTRAZENECA AB 发明人 STEPHEN CONNOLLY;ALEXANDER HUMPHRIES;KATHERINE ELISABETH WILEY;ADRIAN FISHER;ANDREW JAMES WATTS
分类号 A61K31/428;A61P11/06;A61P11/08 主分类号 A61K31/428
代理机构 代理人
主权项
地址